Artal Group S.A.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Artal Group S.A. reported 2 stock positions worth $931.1 million. Its top holding was Cava (CAVA) at 54.9% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 45.1%). Compared with Q1 2026, it added to 1 and reduced 1. The biggest buy was Lexicon Pharmaceuticals (LXRX, shares +13%) and the biggest sale Cava (CAVA, shares −32%).
- Most Recent 13F
- Q2 2026
- Location
- LUXEMBOURG, N4
- CIK
- 0001053906
- Portfolio Value
- $931.1M (Q2 2026)
- SEC Filing
- 0001053906-26-000008 ↗ filed Aug 13, 2026
Holdings Value
Holdings 2 stocks · $931.1M
Portfolio Sells Q1 2026 → Q2 2026
| CAVA Cava Group Inc. | Reduce -31.6% | 54.85% | −21.26 |
Portfolio Buys Q1 2026 → Q2 2026
| LXRX Lexicon Pharmaceuticals Inc. | Add +13.2% | 45.15% | +21.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 2 | $931.1M | CAVA, LXRX |
| Q1 2026 | 2 | $1.0B | CAVA, LXRX |
| Q4 2025 | 2 | $714.6M | CAVA, LXRX |
| Q3 2025 | 2 | $758.2M | CAVA, LXRX |
| Q2 2025 | 2 | $930.2M | CAVA, LXRX |
| Q1 2025 | 2 | $884.2M | CAVA, LXRX |
| Q4 2024 | 2 | $1.2B | CAVA, LXRX |
| Q3 2024 | 2 | $2.4B | CAVA, LXRX |
| Q2 2024 | 108 | $3.9B | CAVA, LXRX, SRRK, KYMR, MORF |
| Q1 2024Amended | 107 | $3.9B | CAVA, LXRX, SRRK, KYMR, ARWR |